PRESS RELEASE published on 04/30/2024 at 12:30, 1 year 11 months ago Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation Immunic announces publication of extended data from phase 2 EMPhASIS trial of Vidofludimus Calcium in RRMS in Neurology Neuroimmunology & Neuroinflammation journal Immunic Vidofludimus Calcium EMPhASIS Trial Neurology Journal RRMS
PRESS RELEASE published on 04/30/2024 at 12:30, 1 year 11 months ago Zomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ET Zomedica Corp. to discuss Q1 2024 financial results on May 9th, 2024, in a conference call and webcast. Company focuses on veterinary health products for animals Conference Call Webcast Zomedica Corp. Veterinary Health Q1 2024 Financial Results
PRESS RELEASE published on 04/30/2024 at 12:30, 1 year 11 months ago iFabric Corp. Receives FDA Medical Device Registration for Apparel Products Utilizing Multiple Textile Technologies iFabric Corp.'s subsidiary IFTNA obtains FDA registration for medical device, showcasing commitment to textile innovation in healthcare. CEO Beevis highlights benefits and growth opportunities Healthcare Innovation Textile Technologies IFabric Corp. IFTNA FDA Registration
PRESS RELEASE published on 04/30/2024 at 12:30, 1 year 11 months ago Planet 13 Launches New MEDIZIN Branded Topicals - Introducing MEDIZIN Rest, Recovery and Relief Planet 13 Holdings Inc. introduces new CBD hemp and cannabis derived topical line under the MEDIZIN brand, expanding product offerings and revenue streams. The topicals incorporate Ovation Science's Invisicare® technology for enhanced delivery of cannabinoids Planet 13 Holdings Inc. Ovation Science MEDIZIN Brand CBD Hemp Cannabis Derived Topicals
PRESS RELEASE published on 04/30/2024 at 12:30, 1 year 11 months ago NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon NanoViricides reports successful completion of Phase I Clinical Trial of NV-387, progresses towards Phase II discussion with physicians and experts for dosing protocol determination NanoViricides NV-387 Phase I Clinical Trial Phase II Discussion Antiviral Drug
PRESS RELEASE published on 04/30/2024 at 12:26, 1 year 11 months ago Alina Holdings PLC:Annual Financial Report Alina Holdings PLC announces its audited results for the year ended 31 December 2023, including financial highlights and property assets review Annual Report Financial Review Audited Results Alina Holdings PLC Property Assets
REGULATED PRESS RELEASE published on 04/30/2024 at 12:20, 1 year 11 months ago Annual Ordinary Shareholders’ Meeting of May 23, 2024, availability of preliminary documents for the Annual General Meeting Safran announces availability of preliminary documents for the Annual Ordinary Shareholders' Meeting to be held on May 23, 2024 at Safran Campus, Massy, France Safran Shareholders Annual Meeting Shareholder Participation Preliminary Documents
REGULATED PRESS RELEASE published on 04/30/2024 at 12:20, 1 year 11 months ago Assemblée Générale Ordinaire du 23 mai 2024, modalités de mise à disposition des documents préparatoires Safran tient son Assemblée Générale Ordinaire le 23 mai 2024. Modalités de participation disponibles en ligne. Possibilité de voter par correspondance ou par Internet Safran Assemblée Générale Participation Modalités Vote Par Correspondance
PRESS RELEASE published on 04/30/2024 at 12:05, 1 year 11 months ago MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials MindBio Therapeutics Corp. announces world first clinical trials in women's health using MB22001, a proprietary form of LSD for PMS treatment Clinical Trials MindBio Therapeutics Corp. MB22001 Women's Health PMS Treatment
PRESS RELEASE published on 04/30/2024 at 12:05, 1 year 11 months ago MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials MindBio Therapeutics Corp. has received regulatory approval for clinical trials using MB22001 to address PMS and PMDD in menstruating individuals. The trials aim to assess the drug's mood-related effects during different menstrual phases Clinical Trials MindBio Therapeutics Corp. MB22001 PMS PMDD
Published on 04/22/2026 at 23:00, 3 hours 16 minutes ago Green Bridge Metals Clarifies Certain Technical Disclosure
Published on 04/22/2026 at 21:30, 4 hours 46 minutes ago Taranis Resources Advances District‑Scale Discovery Across Its Expanded Land Position at Thor
Published on 04/22/2026 at 16:00, 10 hours 16 minutes ago Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance
Published on 04/22/2026 at 15:15, 11 hours 1 minute ago Karbon-X Highlights SkyXero on Earth Day, Bringing Real-Time Climate Action to Travel
Published on 04/23/2026 at 02:05, 10 minutes ago Strong results achieved in world-first Graphene enhanced cement roof tile trial
Published on 04/22/2026 at 22:55, 3 hours 21 minutes ago Assemblée générale ordinaire d’Espace Real Estate Holding SA
Published on 04/22/2026 at 22:05, 4 hours 11 minutes ago Abivax présentera des données sur l’obefazimod lors de la Digestive Disease Week
Published on 04/22/2026 at 22:05, 4 hours 11 minutes ago Abivax to Present Data on Obefazimod at Digestive Disease Week®
Published on 04/22/2026 at 20:55, 5 hours 20 minutes ago xTool Launches WonderPress: The World's First 5-in-1 Heat Creative Hub for Makers and Small Businesses
Published on 04/22/2026 at 17:45, 8 hours 31 minutes ago Cie du Bois Sauvage: Tijdens de Gewone en Buitengewone Algemene Vergaderingen van 22 april 2026 werden alle agendapunten goedgekeurd
Published on 04/22/2026 at 17:45, 8 hours 31 minutes ago Air Liquide to invest over 350M USD to support steel industry and strengthen its footprint in Louisiana
Published on 04/22/2026 at 17:45, 8 hours 31 minutes ago Cie du Bois Sauvage : Tous les points à l'ordre du jour des Assemblées Générales Ordinaire et Extraordinaire du 22 avril 2026 ont été approuvés
Published on 04/22/2026 at 17:45, 8 hours 31 minutes ago Cie du Bois Sauvage: All agenda items of the Ordinary and Extraordinary General Meetings of April 22nd, 2026 have been approved
Published on 04/22/2026 at 17:45, 8 hours 31 minutes ago Air Liquide va investir plus de 350 millions USD pour soutenir l'industrie sidérurgique et renforcer sa présence en Louisiane